Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Decoy TherapeuticsDCOY -3.20%23 Receivables Turnover is 0.00 as of Mar. 2026. GuruFocus rates DCOY with a GF Score™ of 23/100. The stock has 3 warning signs investors should review. Among 843 Biotechnology companies, Decoy Therapeutics ranks worse than 118623.84% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Decoy Therapeutics's Revenue for the
three
months ended in Mar. 2026 was $0.00 Mil. Decoy Therapeutics's average Accounts Receivable for the
three
months ended in Mar. 2026 was $0.00 Mil.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Decoy Therapeutics Receivables Turnover Related Terms
Decoy Therapeutics Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Decoy Therapeutics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DCOY vs PKTX, CASIF, VRAX: Receivables Turnover Comparison
For the Biotechnology subindustry, Decoy Therapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Decoy Therapeutics Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Decoy Therapeutics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Decoy Therapeutics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Decoy Therapeutics (DCOY) has a Receivables Turnover of 0.00 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Decoy Therapeutics and its competitors. According to the industry distribution chart, Decoy Therapeutics ranks #999999 out of 843 companies in the Biotechnology industry.
Is Decoy Therapeutics' Receivables Turnover too high?
Decoy Therapeutics' current Receivables Turnover is 0.00. Based on the distribution chart, Decoy Therapeutics ranks #999999 out of 843 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Decoy Therapeutics has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Decoy Therapeutics' Receivables Turnover compare to PKTX and CASIF?
According to the Biotechnology industry distribution chart, Decoy Therapeutics ranks #999999 out of 843 companies for Receivables Turnover. This places Decoy Therapeutics in the lower half of its industry. The industry median Receivables Turnover is 5.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.26, based on 843 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Decoy Therapeutics and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Decoy Therapeutics's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Decoy Therapeutics stock overvalued right now?
Decoy Therapeutics (DCOY) has a current Receivables Turnover of 0.00. The current Receivables Turnover is 0.00. Decoy Therapeutics' overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Decoy Therapeutics (DCOY), the current Receivables Turnover is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.
23GF Score
Get the complete analysis for DCOY
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DCOY has been successfully added to your 
